Dec. 5 at 5:00 AM
$CRDF Ideal Acquisition Timing:
The optimal moment is before Phase 3 begins — after mature Phase 2 data proves the drug works, but before Cardiff prices itself like a Phase 3 asset.
This is where Pfizer gets the highest expected ROI and reduces risk without paying Phase 3–level premiums.
“Sweet Spot”> After mature Phase 2 data (ORR, CRs, DoR, trend in PFS) but before Phase 3 starts.
Why this is ideal for Pfizer:
1. Risk-reward sweet spot
• Efficacy signal is proven (CRs + ORR > historical SOC).
• Biology validated (RAS-mutated tumors respond).
• Safety profile confirmed as clean.
2. Avoids paying the 3×–5× valuation jump that comes once Phase 3 is initiated and derisks commercial timelines.
3. Pfizer loves acquiring mid-stage oncology assets
Examples:
• Array BioPharma (BRAF/MEK) — acquired pre–Phase 3 readout.
• Trillium (immunotherapy) — acquired at Phase 1b/2.
• Seagen bought for commercial + pipeline, but historically Pfizer acquires early.
